Participate in your choice of 13+ CME/CE symposia held each day of the Congress. Symposia include meals or refreshments and are events that fill up quickly. Register for CMHC today to sign up for these value-added CME/CE activities-included with your registration.
Thursday, October 22, 2015 · CME Breakfast Symposium A
Current Controversies and Novel Insights into Lipid Management: The Good, the Bad and the Ugly?
Faculty: Michael H. Davidson, MD (Chair); Sergio Fazio, MD; Robert S. Rosenson, MD
Low concentrations of HDL-C are consistently associated with elevated CVD risk. However, whether or not raising HDL-C leads to reduced CVD risk is a topic of extensive debate that requires further investigation. Currently, commonly utilized pharmacologic approaches for the treatment of dyslipidemia and subsequent management of ASCVD do not specifically target HDL-C. CETP inhibitors are a novel class of agents that have been demonstrated in clinical trials to increase HDL-C and reduce LDL-C levels. This CME/CE certified symposium and enduring Webcast activity will address the issue of residual ASCVD risk left behind by current lipid-modifying therapies and explore current controversies in HDL, HDL functionality, the potential role of CETP inhibition, and review current CETP inhibitors in development as well as discuss the distinct lipid-altering features of CETP inhibitors (ie, LDL and Lp(a) lowering).
Supported by an educational grant from Lilly
Thursday, October 22, 2015 · CME Breakfast Symposium B
Hypertriglyceridemia - A Neglected CVD Risk Factor: Getting to the Heart of the Matter
Faculty: Christie M. Ballantyne, MD (Chair); Henry N. Ginsberg, MD; Michael Miller, MD
Hypertriglyceridemia is associated with increased cardiovascular (CV) risk and, if severe, pancreatitis. The significance of hypertriglyceridemia as a CV risk factor and therapeutic target, however, has been underestimated for many years. During this unique Expert Roundtable, our expert faculty will blend debate with discussion in an informal conversation, and address the controversy that persists surrounding elevated triglyceride levels as an independent risk factor for CVD. They will explore differing points of view and perspectives to bring novel science and expert opinion to the forefront of discussion. Additionally, data on genetic influences on hypertriglyceridemia will be reviewed and the evidence on the use of available and novel therapies for managing this high-risk population will be carefully examined.
Supported by an educational grant from AstraZeneca
Thursday, October 22, 2015 · CME Lunch Symposium A
DEEP DIVE INTENSIVE
GOING BEYOND "EAT LESS AND MOVE MORE": PROACTIVE AND PROGRESSIVE APPROACHES IN OBESITY MANAGEMENT
Faculty: Robert H. Eckel, MD (Chair); Harold E. Bays, MD; Deborah Bade Horn, DO, MPH; Samuel Klein, MD
This symposium will explore obesity as a multifactorial, recurring disorder, with key genetic and environmental drivers. New genetic and epigenetic insights will provide an understanding of the inheritance, development, and treatment of obesity. Faculty experts will explain the role of CNS pathways and key gastric hormones involved in the regulation of food intake, energy homeostasis, and body weight. This information will challenge practitioners to acknowledge obesity as a serious disease, and help overcome common stigmas and barriers to treatment and maintenance.
Supported by educational grants from Novo Nordisk, Inc. and Takeda Pharmaceuticals International, Inc., US Region.
Thursday, October 22, 2015 · CME Lunch Symposium B
A CLOSER LOOK AT CV OUTCOMES FOR TYPE 2 DIABETES THERAPIES: IMPLICATIONS FOR PATIENT CARE
Faculty: Jay S. Skyler, MD (Chair); Deepak L. Bhatt, MD, MPH; Jennifer B. Green, MD; Darren K. McGuire, MD, MHSc
Patients with type 2 diabetes mellitus are at risk for cardiovascular disease and reducing this risk is a desirable outcome of therapy. Conflicting research on the CV benefits of glucose lowering and the safety of diabetes therapies have led to questions in the medical community. The pursuit of accurate glycemic control and of other CV risk factors may be needed to reduce risk. In this symposium, faculty will examine the latest evidence evaluating the CV outcomes of newer diabetes therapies in relation to potential risks and benefits. Case studies will demonstrate how to integrate these new data into clinical practice.
Supported by an educational grant from Merck & Co., Inc.
Thursday, October 22, 2015 · CME Lunch Symposium C
The Faces of Lipodystrophy: Contemporary Diagnosis and Management Strategies for an Unrecognized Cardiometabolic Disorder
Faculty: Abhimanyu Garg, MD (Chair); Elaine K. Cochran, CRNP; Vinaya Simha, MBBS, MD; Dwanna Swan, PhD
Lipodystrophy is a group of rare syndromes characterized by selective loss of adipose tissue from various parts of the body. This symposium will be framed around case studies that introduce, highlight, and/or reinforce key presentation and discussion topics related to lipodystrophy, including its metabolic consequences and the impact of these consequences on long-term outcomes. Novel therapies, including the FDA-approved leptin replacement therapy, have been shown to reduce the metabolic consequences of some subtypes of lipodystrophy. Expert faculty, along with a lipodystrophy patient advocate, will seek to put a face to the disease and educate the audience on the importance of early recognition and treatment.
Supported by an educational grant from Aegerion Pharmaceuticals, Inc.
Endorsed by Lipodystrophy United
Thursday, October 22, 2015 · CME Dinner Symposium
DEEP DIVE INTENSIVE
NOVEL THERAPIES FOR LDL-C LOWERING IN THE FIGHT AGAINST RESIDUAL ASCVD RISK
Faculty: Christie M. Ballantyne, MD (Chair); Jay D. Horton, MD; Patrick M. Moriarty, MD; Jennifer G. Robinson, MD, MPH
During this comprehensive learning experience, expert faculty will examine current lipid guidelines, the unmet need and residual risk of poorly controlled LDL-C, and exciting genetic insights that have expanded treatment targets. Attendees will leave with the latest information on novel LDL lowering therapies, including PCSK9 inhibitors. Clinical case examples will provide tactics for treatment intensification and how best to integrate new therapies into management plans for high-risk patients.
Supported by educational grants from Genzyme, a Sanofi company, sanofi-aventis U.S., and Regeneron Pharmaceuticals
Friday, October 23, 2015 · CME Breakfast Symposium A
A Conversation with the Experts: New Scientific, Genetic, and Clinical Insights into the Management of Triglycerides
Faculty: Peter H. Jones, MD (Chair); Sekar Kathiresan, MD; R. Preston Mason, MBA, PhD; Howard S. Weintraub, MD
Hypertriglyceridemia is a highly prevalent, yet modifiable, risk factor for pancreatitis, cardiovascular disease (CVD) and associated complications. Despite evidence linking elevated serum triglycerides to cardiovascular (CV) events, a wide gap separates national treatment recommendations and real world practices, leaving patients at risk for excess morbidity and mortality. With several pharmacologic therapies now available for severe hypertriglyceridemia, clinicians must be well informed regarding the safety, efficacy, and tolerability of these agents alone and in combination with statins.
During this Expert Roundtable format, faculty will address educational gaps and learning objectives through brief didactic presentations based on recent data and supportive information within the discussion topic. The moderator will then engage expert panelists in a lively discourse in an informal roundtable conversation.
Supported by an educational grant from Amarin Pharma, Inc.
Friday, October 23, 2015 · CME Breakfast Symposium B
Improving CVD Risk Reduction in African Americans: A Call to Action
Faculty: Clyde W. Yancy, MD, MSc, MACP (Chair); Keith C. Ferdinand, MD; Gary Puckrein, PhD
Racial disparity in hypertension and hypertension-related outcomes, including heart failure, has been recognized for decades with African Americans. African Americans develop hypertension and heart failure at an earlier age and experience worse disease severity as compared with whites. Thousands of African Americans with heart failure die needlessly every year due to the nation's failure to treat them to the standard of care. During this unique Expert Roundtable, our faculty will address the processes contributing to heart failure in African Americans, its management, and challenges with regard to disparities. It will serve as a Call to Action urging healthcare professionals to address these disparities by embracing the current standards of care for African Americans with hypertension and heart failure.
Supported by an educational grant from Arbor Pharmaceuticals, LLC
Friday, October 23, 2015 · CME Lunch Symposium A
THE ROLE OF COMBINATION THERAPIES IN EARLY, INTENSIVE TREATMENT OF TYPE 2 DIABETES: PATIENT-CENTERED APPROACHES TO IMPROVE GLUCOSE CONTROL AND REDUCE CARDIOMETABOLIC RISK FACTORS
Faculty: John B. Buse, MD, PhD (Chair); Lawrence Blonde, MD; Samuel Dagogo-Jack, MD; Carol H. Wysham, MD
Despite the availability of numerous treatment options for type 2 diabetes mellitus, the number of patients achieving glycemic goals is unacceptably low. Some existing glucose-lowering agents have adverse effects such as weight gain or hypoglycemia. Newer treatment options are now available or under development that may work synergistically with other available interventions to achieve glycemic control, reduce overall cardiometabolic risk, and improve adherence and satisfaction for individuals with T2DM. This symposium will provide practical strategies to individualize goals and therapies based on patient characteristics, disease factors, and patient priorities.
Supported by an educational grant from AstraZeneca.
Friday, October 23, 2015 · CME Lunch Symposium B
New Insights into the Prevention and Clinical Management of Hyperkalemia
Faculty: George L. Bakris, MD (Chair); Bertram Pitt, MD; Matthew R. Weir, MD
Hyperkalemia occurs frequently in patients with heart failure, chronic kidney disease, and/or hypertension and can be life-threatening if not treated promptly. Although only one FDA-approved treatment option currently exists, newer therapies are now in development that may provide safer, more consistent management of the condition. This symposium will engage the nation's leading experts in a lively exchange as they discuss recent updates in the prevention and management of hyperkalemia as well as strategies for individualizing care for hyperkalemic patients.
Supported by an educational grant from Relypsa, Inc.
Friday, October 23, 2015 · CME Lunch Symposium C
CLINICAL ADVANCES SPOTLIGHT
Advances in LDL Lowering: A Focus on PCSK9 Inhibitors' Journey from Genetics to Clinical Practice
Faculty: Marc S. Sabatine, MD (Chair); Seth J. Baum, MD; Michael J. Koren, MD; James A. Underberg, MD
One of the more remarkable scientific advances of this century is the discovery of PCSK9, which the body uses to regulate LDL-C. In little more than a decade, the first PCSK9 inhibitors have received FDA approval. This Clinical Advances will highlight key events that allowed for rapid development of the drug from bench to bedside. It will also discuss the relationship between atherosclerosis progression and LDL-C levels and provide expert interpretation of clinical guidelines on lipid management and clinical trial results. An interactive panel discussion will explore how PCSK9 inhibitors can be integrated into the management of patients with severe lipid disorders to help achieve lipid management goals, reduce cardiovascular risk, improve outcomes for patients, and potentially in the future, even be used as primary prevention.
Supported by an educational grant from Amgen, Inc.
Friday, October 23, 2015 · CME Dinner Symposium
PAVING THE WAY TO PATIENT ACCEPTANCE, ADHERENCE, AND SATISFACTION: THE ROLE OF NEXT-GENERATION INSULIN THERAPIES
Faculty: Matthew C. Riddle, MD (Chair) Daniel Einhorn, MD; Martha M. Funnell, MS, RN, CDE; Anne L. Peters, MD
This symposium will discuss common roadblocks to the initiation of and adherence to insulin therapy as well as provide strategies to overcome these barriers. Experts will present evidence-based strategies for integrating the latest in insulin therapies and technologies into an overall diabetes management program to improve glycemic control, reduce risk of hypoglycemia, and make insulin therapy more convenient, manageable, and effective.
Supported by an educational grant from Novo Nordisk, Inc.
Saturday, October 24, 2015 · CME Breakfast Symposium
The Evolution of Insulin Therapy: New Developments in Treatment, Technology, and Methods of Administration
Faculty: Anne L. Peters, MD (Chair); Martin J. Abrahamson, MD; Howard A. Wolpert, MD
Many patients with type 2 diabetes are reticent about initiating insulin, so therapies that allow insulin treatment to be more tailored to individual needs are likely to result in greater acceptance and patient adherence with therapy. Insulin treatments are newly available and in development that aim to increase absorption rate, prolong the duration of action, reduce peak variability and weight gain, and offer alternative delivery methods. This symposium will describe the evolution of insulin therapy and explore novel and emerging therapies, new devices for insulin delivery, and novel technology that make monitoring glucose more convenient.
Supported by an educational grant from sanofi USBack to 10th Annual CMHC Home